^
Association details:
| Biomarker: | EPHA2 G391R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | sirolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
Excerpt:
Cell survival of BEAS-2B control, empty vector (EV), EphA2 wild-type (WT), or EphA2 G391R mutant-expressing cells in culture was assayed in the presence of varying rapamycin concentrations. Survival drops sharply with a 10−5 M (10 μM) rapamycin dose; this effect is more pronounced in cells harboring the G391R mutation. Statistical significance between WT and G391R cells is indicated for 10−6 M (1 μM) and 10−5 (10 μM) rapamycin concentrations...
DOI:
10.1074/jbc.M109.075085
